KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients.

ABSTRACT:

Background

The administration of docetaxel chemotherapy is one therapeutic option to delay disease progression and increase overall survival in metastatic castration resistant prostate cancer (mCRPC). However, about 15% of patients are primary resistant to chemotherapy and hence would benefit from an alternative mCRPC treatment. Despite intensive research, there are no robust clinical validated biomarkers to predict mCRPC therapy response. Thus, the aim of the study was to determine KDM5D expression in archival radical prostatectomy specimens of patients medicated with docetaxel at time of mCRPC development in order to correlate KMD5D expression with treatment response.

Methods

We used in situ hybridization (ISH) (RNA scope 2.5 HD) to determine KDM5D expression in tissue sam

SUBMITTER: Schafer G 

PROVIDER: S-EPMC8575572 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature